Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA
Patients with diffuse large B cell lymphoma (DLBCL) exhibit marked diversity in tumor
behavior and outcomes, yet the identification of poor-risk groups remains challenging. In …
behavior and outcomes, yet the identification of poor-risk groups remains challenging. In …
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma
T Philip, C Guglielmi, A Hagenbeek… - … England Journal of …, 1995 - Mass Medical Soc
Background High-dose chemotherapy followed by autologous bone marrow transplantation
is a therapeutic option for patients with chemotherapy-sensitive non-Hodgkin's lymphoma …
is a therapeutic option for patients with chemotherapy-sensitive non-Hodgkin's lymphoma …
Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study
M Roschewski, K Dunleavy, S Pittaluga… - The Lancet …, 2015 - thelancet.com
Background Diffuse large-B-cell lymphoma is curable, but when treatment fails, outcome is
poor. Although imaging can help to identify patients at risk of treatment failure, they are often …
poor. Although imaging can help to identify patients at risk of treatment failure, they are often …
Etoposide: twenty years later
JD Hainsworth, FA Greco - Annals of Oncology, 1995 - Elsevier
Etoposide, a semisynthetic glucosidic derivative of podophyllotoxin, is diagrammed in Fig. 1.
Etoposide is one of the most active and useful antineoplastic agents, and is now used …
Etoposide is one of the most active and useful antineoplastic agents, and is now used …
[HTML][HTML] Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish …
R Garcia-Sanz, A Sureda, F de la Cruz, M Canales… - Annals of …, 2019 - Elsevier
Background In this work, we assessed the efficacy and safety of brentuximab vedotin (BV)
plus ESHAP (BRESHAP) as second-line therapy for Relapsed/Refractory Hodgkin …
plus ESHAP (BRESHAP) as second-line therapy for Relapsed/Refractory Hodgkin …
Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell …
PA Hamlin, AD Zelenetz, T Kewalramani, J Qin… - Blood, 2003 - ashpublications.org
Second-line chemotherapy followed by high-dose therapy (HDT) with autologous stem cell
transplantation (ASCT) cures less than half of the patients with relapsed or refractory diffuse …
transplantation (ASCT) cures less than half of the patients with relapsed or refractory diffuse …
[HTML][HTML] Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease
A Josting, C Rudolph, M Reiser, M Mapara, M Sieber… - Annals of …, 2002 - Elsevier
Background An important variable affecting outcome in relapsed and refractory Hodgkin's
disease (HD) is the potential of conventional salvage chemotherapy to reduce tumor volume …
disease (HD) is the potential of conventional salvage chemotherapy to reduce tumor volume …
[HTML][HTML] Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse
A Sureda, M Constans, A Iriondo, R Arranz… - Annals of …, 2005 - Elsevier
Purpose To analyse outcome and prognostic factors for overall survival (OS) and time to
treatment failure (TTF) in 357 patients with Hodgkin's lymphoma (HL) undergoing an …
treatment failure (TTF) in 357 patients with Hodgkin's lymphoma (HL) undergoing an …
Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab
TA Davis, CA White, AJ Grillo-Lopez… - Journal of Clinical …, 1999 - ascopubs.org
PURPOSE: A phase II trial was performed to evaluate the safety and efficacy of rituximab, a
chimeric anti-CD20 monoclonal antibody, in patients with bulky (> 10-cm lesion) relapsed or …
chimeric anti-CD20 monoclonal antibody, in patients with bulky (> 10-cm lesion) relapsed or …
Evolution of lymphoma staging and response evaluation: current limitations and future directions
J Cunningham, S Iyengar, B Sharma - Nature Reviews Clinical …, 2017 - nature.com
The accurate detection and precise assessment of therapeutic responses is critical to the
optimal management of patients with lymphoma. Over the past 50 years, dramatic advances …
optimal management of patients with lymphoma. Over the past 50 years, dramatic advances …